Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477840 | 0.86 | — | — | |
| SCHEMBL5412612 | 0.77 | CES2 (0.48) | CES2CES1HDAC8HDAC6TSHR | |
| Acetic Acid SCHEMBL8655535 | 0.76 | CES2 (0.52) | CES2CES1HDAC8HDAC6TSHR | |
| Acetic Acid SCHEMBL2778031 | 0.76 | CES2 (0.52) | CES2CES1HDAC8HDAC6TSHR | |
| Acetone SCHEMBL11154504 | 0.76 | CES2 (0.52) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL4656363 | 0.75 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL1043598 | 0.75 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL479710 | 0.75 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL2867269 | 0.75 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL479450 | 0.75 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0643059-A1 | 3-(3-Pyridinyl)-1H-indoles as thromboxane A2 synthetase inhibitors | Pfizer Limited (GB) | 1995-03-15 | — | — | EP | claimed |
| EP-0594588-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1994-05-04 | — | — | EP | claimed |
| EP-0358398-B1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1993-03-10 | — | — | EP | claimed |
| WO-1991013054-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1991-09-05 | — | — | WO | claimed |
| EP-0358398-A1 | Cycloalkyl-substituted glutaramide antihypertensive agents | Pfizer Limited (GB) | 1990-03-14 | — | — | EP | claimed |
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-7659271-B2 | Pyrimidine compound having dibenzylamine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-2149563-A1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | Kowa Company. Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | KOWA COMPANY, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-0643059-A1 | 3-(3-Pyridinyl)-1H-indoles as thromboxane A2 synthetase inhibitors | Pfizer Limited (GB) | 1995-03-15 | — | — | EP | disclosed |
| EP-0594588-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1994-05-04 | — | — | EP | disclosed |
| EP-0558656-A1 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES. | MASSACHUSETTS INST TECHNOLOGY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0358398-B1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1993-03-10 | — | — | EP | disclosed |
| WO-1992009545-A2 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1991013054-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1991-09-05 | — | — | WO | disclosed |
| US-4975444-A | INHIBITORS OF ANGIORENSIN-CONVERTING ENZYME AS WELL AS A ENDOPEPTIDASE; CARDIOTONIC AGENTS; GLAUCOMA; DIURETICS | PFIZER INC. (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0358398-A1 | Cycloalkyl-substituted glutaramide antihypertensive agents | Pfizer Limited (GB) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | CETP, NPC1L1, MTTP | CES2 88/4885CES1 7/4885HDAC8 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.